Lorundrostat, a selective aldosterone synthase inhibitor, significantly reduced systolic blood pressure in patients with ...

Mineralys Therapeutics, Inc.’s MLYS share price has dipped by 6.67%, which has investors questioning if this is right time to ...

A comprehensive new review by researchers at the University of Kentucky sheds light on the intricate and damaging ...

Participants with uncontrolled and otherwise treatment-resistant hypertension showed significant blood pressure improvement ...

Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and ...

Discover how your kidneys and blood pressure are secretly linked, plus 6 vital strategies to protect both systems and prevent ...

Advances in hypertension as reported at ACC 2025 include two new therapies that achieve significant blood pressure (BP) ...